Analyst Price Target is $12.63
▲ +210.20% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for DarioHealth in the last 3 months. The average price target is $12.63, with a high forecast of $15.00 and a low forecast of $7.50. The average price target represents a 210.20% upside from the last price of $4.07.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in DarioHealth. This Buy consensus rating has held steady for over two years.
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.